Monroe facility FDA reinspection delay
Remediation completed but FDA reinspection pending; delay could impact injectable commercialization timeline.
GLENMARK / Q4-FY24 / risks
Keep the risk register visible.
Glenmark Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Elevated legal settlement cash outflows
Cash payout of ~INR 300 crore in FY25 for DOJ and Zetia settlements, impacting free cash flow.
North America revenue decline and lack of launches
North America revenue fell 12.4% YoY; recovery depends on generic Flovent approval and scale-up of recent launches.
IGI R&D spend remains high at $50 million
Despite earlier guidance to reduce Ichnos spend, FY25 IGI cash R&D is $50 million, pressuring profitability.